Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
- 31 December 2007
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 116 (3), 496-526
- https://doi.org/10.1016/j.pharmthera.2007.09.004
Abstract
No abstract availableFunding Information
- Vetenskapsrådet
- Swedish Cancer Foundation
- Ministerio de Educación, Cultura y Deporte
This publication has 99 references indexed in Scilit:
- Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiencyMolecular Genetics and Metabolism, 2007
- The Convergence of Conventional Therapeutic Drug Monitoring and Pharmacogenetic Testing in Personalized Medicine: Focus on AntidepressantsClinical Pharmacology & Therapeutics, 2007
- CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor SaquinavirClinical Pharmacology & Therapeutics, 2007
- Global variation in copy number in the human genomeNature, 2006
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Approaches to microRNA discoveryNature Genetics, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazamBrain & Development, 2004
- A COMPARISON OF HEPATIC CYTOCHROME P450 PROTEIN EXPRESSION BETWEEN INFANCY AND POSTINFANCYLife Sciences, 1997
- CpG Islands in vertebrate genomesJournal of Molecular Biology, 1987